ZM 02
Alternative Names: ZM-02Latest Information Update: 08 Mar 2024
At a glance
- Originator Zhongmou Therapeutics
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Age-related macular degeneration; Retinitis pigmentosa
Most Recent Events
- 25 Feb 2024 Zhongmou Therapeutics plans a phase 0 trial for Retinitis Pigmentosa in China in February 2024 (Intravitreal) (NCT06292650)
- 09 Oct 2023 Preclinical trials in Age-related macular degeneration in China (Parenteral) (Zhongmou Therapeutics pipeline, October 2023)
- 09 Oct 2023 Preclinical trials in Retinitis pigmentosa in China (Parenteral) (Zhongmou Therapeutics pipeline, October 2023)